COVID-19 Vaccine
 

COVID-19 Vaccine Eligibility Criteria


All people in Manitoba aged 6 months and older are eligible for COVID-19 vaccination. This page provides information about vaccine eligibility and recommendations on the type of vaccine people should receive. If you have questions about your individual circumstances, including your individual risks and benefits of vaccination, please speak with your health care provider.

Canada's National Advisory Committee on Immunization (NACI) makes COVID-19 vaccine specific recommendations for people of all ages. These recommendations and guidance from NACI are available here.

You can also review the information below in this table developed by Manitoba Health, which shows the recommended mRNA immunization schedule based on age.


On this page


Other important information

You can make your vaccine appointment at some sites online or by calling 1-844-626-8222. The vaccine is also available from medical clinics, pharmacies and other locations. Use the Vaccine Finder to find a convenient location.

It's helpful to know when you received your previous doses of COVID-19 vaccine and the type of vaccine you received. If you do not recall this information and you have a Manitoba health card, you can locate it at: sharedhealthmb.ca/covid19/test-results/. If your immunization record is incomplete or incorrect, or you received a COVID-19 vaccination outside of Manitoba, you can have your file updated by completing and submitting this e-form.

You will need to complete a consent form for every COVID-19 vaccine you receive. Filling out the form in advance can make it faster for you to get your vaccine. Click here to fill out and print your consent form.




Children aged 6 months to 4 years


All children in this age group are eligible to receive a primary COVID-19 vaccine series. A primary series consists of two doses. Booster doses are not available for this age group at this time.

There are two products authorized for children aged six months to four years:

  • Moderna: The primary series consists of two doses. The interval between the first and second dose for most children is eight weeks.
  • Pfizer: The primary series consists of three doses. The interval between doses is eight weeks.

It is recommended to start and finish the primary series with the same product.

Children must be at least six months of age at the time of their immunization appointment.

Parents/guardians who want their child to receive their next dose sooner (before eight weeks) should discuss the risks and benefits with their immunizer or health care provider before vaccination, to ensure the parent/guardian understands the risks of an earlier second dose. A longer time period between doses provides a stronger immune response.

For more information on NACI recommendations, please go to the Canadian Immunization Guide.




Children aged 5 to 11


Children in this age group are eligible to receive a primary COVID-19 vaccine series and a first booster dose.

The pediatric Pfizer vaccine is the preferred vaccine for the primary series

For those who are 5 years old (before their sixth birthday), it is recommended to receive the pediatric Pfizer vaccine, but alternatively they can receive the infant Moderna vaccine.

Children must be five years old at the time of their immunization appointment. The recommended time between first and second doses for most children is eight weeks.

Parents/guardians who want their child to receive their second dose sooner (after 21 days but before eight weeks) should discuss the risks and benefits with their immunizer or health care provider before vaccination. This will ensure the parent/guardian understands the risks of an earlier second dose as a longer time period between doses provides a stronger immune response.

For children living in First Nations communities, the recommended time between first and second doses is 21 days for the pediatric Pfizer vaccine and 28 days for the Moderna vaccine.

Children ages 5 to 11 are now eligible to receive a booster dose with the pediatric Pfizer COVID-19 vaccine. The minimum interval between the primary series and a booster dose is 6 months.

The National Advisory Committee on Immunization (NACI) recommends:

  • the use of Pfizer vaccine for children 5 to 11 years of age because there is more data available from the real-world use of this vaccine.
  • a first booster dose is recommended for children 5 to 11 years of age, who have a health condition that increases their risk of severe illness from COVID-19. For more information on NACIs recommendations, please see COVID:19 vaccine: Canadian Immunization Guide.



Youth and Adults aged 12 and Older


It is recommended that everyone aged 12 and older receive a primary COVID-19 vaccine series and booster doses.

A primary series consists of two doses. The time between the first and second dose is eight weeks. Individuals who wish to receive their second dose sooner (after 28 days but before eight weeks) should discuss the risks and benefits with their immunizer or health care provider before vaccination. Doing so ensures they understand the risks of an earlier second dose, because a longer time period between doses provides a stronger immune response.

Youth aged 12 to 17: The Pfizer vaccine is recommended for all doses, including the primary series and booster doses, due to a lower risk of myocarditis/pericarditis with this vaccine as compared to the Moderna vaccine for this age group.

The National Advisory Committee on Immunization (NACI) also recommends:

  • All youth should be offered a fall booster dose, regardless of the number of booster doses they have previously received.
  • Youth at increased risk of severe illness from COVID-19 are strongly encouraged to receive a fall booster dose. For more information on NACIs recommendations, please see COVID-19 vaccine: Canadian Immunization Guide.

Adults aged 18 years and older: For the primary series, it is recommended to get the same mRNA vaccine, if available. However, a combination of mRNA vaccines is both safe and effective, and either (Pfizer or Moderna) can be offered if:

  • the same mRNA vaccine is not available,
  • your previous dose was with a non-mRNA vaccine (e.g. AstraZeneca, Janssen), or
  • the last dose is unknown.

If you have completed your primary series, all adults are eligible for a fall booster dose, regardless of the number of booster doses they have previously received. 

It’s recommended to wait six months after the last dose of the primary series or your most recent booster before receiving a fall booster.  However, the minimum interval is three months.

There are two types of booster doses available in Manitoba: bivalent and monovalent. NACI recommends the bivalent omicron-containing mRNA COVID-19 vaccines as the preferred booster products for people aged 12 and older.

Book your 2022 fall booster online

Bivalent (Moderna/Spikevax™ Bivalent and Pfizer/Comirnaty™ Bivalent) vaccines have been developed to protect against the original strain of COVID-19 as well as the omicron strain. This type of vaccine provides a broader immune response and may also protect against future variants of concern.

  • The Moderna/Spikevax Bivalent (original/omicron BA.1) vaccine is authorized as a booster dose for individuals 18 years of age and older.
  • The Pfizer/Comirnaty Bivalent (original/omicron BA.4/5) vaccine is authorized as a booster dose for individuals 12 years of age and older.
    • Note: there is no evidence indicating one bivalent vaccine is more effective than the other.

Individuals who choose not to receive a bivalent booster may receive a monovalent booster.

Monovalent (Pfizer/Comirnaty™ and Moderna/Spikevax™) are the original mRNA vaccines which were designed to protect against the initial strain of the COVID-19 virus.

ᵒ  Youth aged 12 to 17 years are eligible to receive a monovalent booster dose of COVID-19 vaccine. The Pfizer/Comirnaty (30 mcg) booster dose is preferred to Moderna Spikevax in this age group.

ᵒ  For adults 18 years of age and older, either mRNA vaccine (Pfizer or Moderna) can be given, regardless of the COVID-19 vaccines previously received.

Individuals who have already received an mRNA COVID-19 vaccine this fall are not eligible for an additional dose at this time. This includes individuals who were vaccinated using any monovalent or bivalent mRNA COVID-19 vaccine. Both will boost immune responses and are likely to provide significant protection against hospitalization and severe disease.




Infants, Children, Youth and Adults who are Moderately to Severely Immunocompromised


For the purposes of COVID-19 vaccine recommendations, the following individuals are considered moderately to severely immunocompromised due to a medical condition and/or treatment:

  • are receiving active chemotherapy (or immunotherapy) for cancer;
  • have received a solid organ transplant and are currently receiving chemotherapy or other immunosuppressive therapy;
  • were born with moderate or severe dysfunction of their immune system;
  • are living with untreated or advanced HIV-AIDS; or
  • are taking certain medications that severely affect the immune system.

The following people should talk to their doctor to see whether they are considered to be immunocompromised:

  • receiving hemodialysis or peritoneal dialysis;
  • are on the list to receive a solid organ transplant; or
  • have a ventricular assist device (VAD).

Most individuals who are eligible for a COVID vaccine get two doses for their primary series. Infants, children, youth and adults who are moderately to severely immunocompromised are recommended to receive an additional dose of COVID-19 vaccine to complete their primary series. The interval between the first and the second dose is eight weeks. The interval between the second and third dose is four to eight weeks.

For infants aged six months to four years who are moderately to severely immunocompromised, the National Advisory Committee on Immunization strongly recommends a three-dose primary series of the Moderna (25 mcg) vaccine. If it is not readily available, a four-dose primary series with the Pfizer (3mcg) vaccine may be offered, with an interval of four to eight weeks between each dose.

Individuals who wish to receive their second dose sooner (after 28 days but before eight weeks) should discuss the risks and benefits with their immunizer or health care provider before vaccination, to ensure they understand the risks of an earlier second dose. A longer time period between doses provides a stronger immune response. The additional dose in the primary series requires a prescription if given outside of a physician or pharmacist office and must be given at least 28 days after the second dose.

NACI strongly recommends that everyone 5 years and older who is at increased risk of severe illness from COVID-19 should be offered a fall COVID-19 vaccine booster dose regardless of the number of booster doses previously received.

It is recommended to wait six months after the last dose of the primary series before getting a booster dose. However, the minimum interval is three months.

It is also recommended for individuals to wait six months since their last COVID-19 infection before getting a booster dose. At minimum, they need to be fully recovered before receiving a booster dose.

Refer to the appropriate sections above for more information on booster doses for children, youth and adults.




Immunization after a COVID-19 infection


It is possible that people will get COVID-19 before starting or completing their COVID-19 vaccine primary series. In this case, it is recommended to wait two months before getting your next dose in the primary series.

If someone gets COVID-19 before getting their booster dose, it is recommended to wait six months before receiving their booster dose. At minimum, they need to be symptom free and no longer isolating before receiving a booster dose.

Recommendations may be different if you are moderately to severely immunocompromised. Please speak to your health care provider to get the best advice on when to get your next vaccine dose after a COVID-19 infection.

For more information on NACI's recommendation on interval between infection and getting your next COVID-19 vaccine dose, please visit: COVID-19 vaccine: Canadian Immunization Guide - Canada.ca.

 


 

Recommended mRNA Immunization Schedule


This table shows the recommended mRNA immunization schedule for people based on their age.

 

Approved COVID- 19 mRNA vaccine

Time between doses of primary series and Number of doses in primary series

Immunocompromised:
Time between doses of primary series and Number of doses in primary series

Time between most recent dose and any booster dose

Approved COVID- 19 booster doses

Infants and children aged 6 months to 4 years

Moderna (25mcg) or
Pfizer (3mcg)

8 weeks
2 doses (Moderna) or 3 doses (Pfizer)

4 - 8 weeks
3 doses (Moderna) or 4 doses (Pfizer)

Not eligible

Not eligible

Children aged 5 years *

Pfizer (10mcg) or

Moderna (25mcg)

8 weeks
2 doses

4 - 8 weeks
3 doses

6 months

 

Pfizer (10mcg)

 

Children aged 6 to 11 years *

Pfizer (10mcg) or

Moderna (50mcg)

8 weeks
2 doses

4 - 8 weeks
3 doses

6 months

 

Pfizer (10mcg)

 

Youth aged 12 to 17 years *

Pfizer (30mcg) or

Moderna (100mcg)

8 weeks
2 doses

4 - 8 weeks
3 doses

6 months

Pfizer bivalent** or Pfizer (30mcg) or Moderna (50/100mcg)

Adults aged 18 to 29 years *

Pfizer (30mcg) or

Moderna (50mcg/100mcg)

8 weeks
2 doses

4 - 8 weeks
3 doses

6 months

Pfizer bivalent or Moderna bivalent** or Pfizer (30mcg) or Moderna (50mcg/100mcg)

Adults aged 30 years and older

Pfizer (30mcg) or

Moderna (50mcg/100mcg)

8 weeks
2 doses

4 - 8 weeks
3 doses

6 months

Pfizer bivalent or Moderna bivalent** or Pfizer (30mcg) or Moderna (50mcg/100mcg)

 

Moderna the recommended mRNA vaccine for immunocompromised infants and children aged 6 months to 4 years old.

 

* Pfizer is the recommended mRNA vaccine for the primary series in individuals aged 5 to 29 years.

 

**A bivalent omicron-containing mRNA COVID-19 vaccine is the preferred booster product. There is no evidence that one bivalent vaccine is more effective than the other.

Note: Moderna 100mcg is offered as a primary series to individuals aged 12 and older and as a first booster dose to individuals at increased risk of severe illness. Moderna 50mcg is offered as a booster dose to individuals aged 12 and older who are not at risk of severe illness.